MedTrace Logo

A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

NCT06977880 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.

Conditions

  • Healthy

Interventions

DRUG

LY4292009

Administered orally

DRUG

Placebo

Administered orally.

Sponsors & Collaborators

  • Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-19
Primary Completion
2026-03-20
Completion
2026-03-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06977880 on ClinicalTrials.gov